Brooks Laboratories Ltd

BSE
BROOKS •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Brooks Laboratories Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
54.48% Fall from 52W High
-17.1
TTM PE Ratio
Negative PE TTM
-11.3
Price to Book Ratio
Below industry Median
3.4
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is negative
-0.4
RSI
RSI is mid-range
42.6
MFI
MFI is mid-range
35.9

Brooks Laboratories Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Brooks Laboratories Ltd shareholding Pattern

Promoter
63.6%
Mutual Funds
3.9%
Public
32.6%
Promoter
63.6%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
32.6%
Promoter
63.6%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
32.6%
Promoter
63.6%
Mutual Funds
2.5%
Public
33.9%
Mutual Funds
1.2%
Promoter
66.4%
Public
33.6%
Promoter
66.4%
Public
33.5%
Domestic Institutions
0.1%

Brooks Laboratories Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
2
Bearish Moving Averages
14
5Day EMA
84.20
10Day EMA
85.00
12Day EMA
85.20
20Day EMA
85.50
26Day EMA
85.90
50Day EMA
89.20
100Day EMA
97.00
200Day EMA
102.60
5Day SMA
84.60
10Day SMA
85.50
20Day SMA
86.40
30Day SMA
84.40
50Day SMA
87.10
100Day SMA
97.70
150Day SMA
113.00
200Day SMA
113.20
Delivery & Volume
Resistance & Support
83.18
Pivot
Resistance
First Resistance
83.95
Second Resistance
84.38
Third Resistance
85.15
Support
First Support
82.75
Second support
81.98
Third Support
81.55
Relative Strength Index
42.64
Money Flow Index
35.93
MACD
-0.76
MACD Signal
-0.58
Average True Range
3.25
Average Directional Index
10.46
Rate of Change (21)
-2.45
Rate of Change (125)
-51.29
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Bafna Pharmaceuticals Ltd.
203.44
73.35
116.45
Lactose (India) Ltd.
-
-
-
Krebs Biochemicals & Industries Ltd.
183.93
60
102.37
Sanjivani paranteral Ltd.
-
-
-
Gennex Laboratories Ltd.
-
-
-
Quest Laboratories Ltd.
-
-
-

Brooks Laboratories Ltd Company background

Founded in: 2002
Brooks Laboratories Limited was incorporated on January 23, 2002. The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers. Brooks Laboratories is a pharmaceutical manufacturing company working on contract basis. The company has manufacturing plants at Baddi, Himachal Pradesh and Vadodara, Gujarat. Both the units are cGMP compliant in conformity with national and international standards. The Vadodara facility of the company has been approved by European Medicine agency. The company has a wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc. Their product portfolio presently comprises of 28 Injectables, 19 Tablets and 2 Dry Syrups which are marketed domestically.The companys manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.The companys major clients are companies like Zydus Cadila, Aristo Pharmaceuticals Pvt Ltd, FDC Ltd, Nectar Lifesciences Ltd, Sanat Products Ltd, Hetero Healthcare Ltd, Medley Pharmaceuticals, Wockhardt Ltd, Parental Drugs, Chanderbhagat Pharma and Alembic Ltd etc. Their major suppliers of raw materials are Rajasthan Antibiotics Ltd, Aurobindo Pharma Ltd, DSM Anti Infectives Ltd and Qilu Pharmaceutical Company Ltd.With roots dating back to 2002, Brooks Laboratories were established with a sole purpose of being a pioneer in the Pharmaceutical industry. Right from its inception, the company has entrenched strong foothold in the Pharmaceutical business and has successfully been a prominent part of Pharmaceutical Formulation Development, Pharmaceutical Production, Pharmaceutical Exports, etc. Starting out as Manufacturer for various Pharmaceutical products in India and abroad, over the years with sheer hard work, the Company earned its valuable name in India and abroad. The Company has a worlds largest dedicated EU certified plant at Vadodara.In the year 2006, the company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development (RD) centre at Baddi, Himachal Pradesh. In May 2006, they started their operations and in June 3, 2006, they commenced commercial production.In October 2006, the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007, they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd, Australia. In April 2008, the company took over some of the assets of Brooks Pharmaceuticals, a partnership firm of the promoters, Atul Ranchal Rajesh Mahajan.In April 2010, the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health Family Welfare, HP. In July 2010, the company received an ISO 9001:2008 Certificate from UKAS Quality Management, URS IAF.In August 2011, Brooks Laboratories raised money by way of Initial Public Offer Rs. 63 Crore from public. During the financial year ended 31 March 2014, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2015, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2016, the company operated the Baddi plant at 92% capacity.On 7 March 2017, Brooks Laboratories world class dedicated carbapenem facility in Vadodara Plant started manufacturing activity. Brooks Management decided to upgrade the facility in line with cGMP in Baddi plant. Since it was a running unit, the company decided to upgrade the Baddi facility in steps. As a first step, the company upgraded one injectable manufacturing line, which started commercial production in November 2016. The company operated the Baddi plant at 92% capacity during the year under review.The upgradation of injectable line in Baddi facility was carried out for 3 months from June 2017, whereby production in injectable line was affected, upgradation was completed and production started from September onwards in Baddi facility. The company commenced production in August 2017 at Baddi Plant with almost double the capacity of previous line.The Company started production and sales at its manufacturing facility in Vadodara in 201920.
Read More

Brooks Laboratories Ltd FAQs

The past 1-year return of Brooks Laboratories Ltd [BROOKS] share was 6.68. The Brooks Laboratories Ltd [BROOKS] share hit a 1-year low of Rs. 72.51 and a 1-year high of Rs. 185.15.

The Mutual Fund Shareholding was 3.86% at the end of .

You can easily buy Brooks Laboratories Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -